Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.48 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.47 |
| ▸ | MDM4 | O15151 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | CPA1 | P15085 | 2/20 | 0.44 |
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | MIF | P14174 | 1/20 | 0.44 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.44 |
| ▸ | CPA2 | P48052 | 1/20 | 0.43 |
| ▸ | CPA4 | Q9UI42 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3048691 | 1.00 | TACR1 (0.50) | TACR1TSHRGRIA1KMT2ANPSR1 | |
| SCHEMBL5887793 | 0.87 | ACACB (0.53) | TACR1ACACB | |
| SCHEMBL5887794 | 0.87 | ACACB (0.53) | TACR1ACACB | |
| SCHEMBL2859966 | 0.87 | ACACB (0.53) | TACR1MMEACEACACB | |
| SCHEMBL5887606 | 0.87 | TACR1 (0.46) | TACR1ACACB | |
| SCHEMBL5887604 | 0.87 | TACR1 (0.46) | TACR1ACACB | |
| SCHEMBL2859969 | 0.87 | ACACB (0.53) | TACR1MMEACEACACB | |
| SCHEMBL5813004 | 0.87 | TACR1 (0.61) | TACR1 | |
| SCHEMBL5812998 | 0.87 | TACR1 (0.61) | TACR1 | |
| SCHEMBL315117 | 0.86 | NPSR1 (0.61) | TACR1TSHRGRIA1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE41339-E1 | N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use | TRISTRATA, INC. (US) | 2010-05-18 | — | — | US | claimed |
| WO-2006119283-A2 | ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE | YU RUEY J (US) | 2006-11-09 | — | — | WO | claimed |
| US-20060251597-A1 | ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE | YU RUEY J | 2006-11-09 | — | — | US | claimed |
| CN-111592490-B | Preparation method of key intermediate of roxasistat | 浙江工业大学 | 2022-04-22 | — | — | CN | disclosed |
| CN-111592490-A | Preparation method of key intermediate of roxasistat | 浙江工业大学 | 2020-08-28 | — | — | CN | disclosed |
| WO-2006119283-A2 | ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE | YU RUEY J (US) | 2006-11-09 | — | — | WO | disclosed |
| US-20060251597-A1 | ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE | YU RUEY J | 2006-11-09 | — | — | US | disclosed |
| CN-1812988-A | Processes for making thiazolidinedione derivatives and compounds thereof | SYNTHON BV (NL) | 2006-08-02 | — | — | CN | disclosed |
| EP-1622898-A1 | PROCESSES FOR MAKING THIAZOLIDINEDIONE DERIVATIVES AND COMPOUNDS THEREOF | Synthon B.V. (NL) | 2006-02-08 | — | — | EP | disclosed |
| US-20050059708-A1 | Processes for making thiazolidinedione derivatives and compounds thereof | SYNTHON BV (NL) | 2005-03-17 | — | — | US | disclosed |
| WO-2004101560-A1 | PROCESSES FOR MAKING THIAZOLIDINEDIONE DERIVATIVES AND COMPOUNDS THEREOF | SYNTHON B.V. (NL) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059708-A1 | Processes for making thiazolidinedione derivatives and compounds thereof | PPARD, PPARG, PPARA | TACR1 1074/4885TSHR 146/4885GRIA1 4045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.